Devyser Diagnostics AB (publ) (STO:DVYSR)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.57B +4.3% |
| Revenue (ttm) | 257.50M +16.5% |
| Net Income | 15.00M |
| EPS | 0.89 |
| Shares Out | 16.79M |
| PE Ratio | 104.84 |
| Forward PE | 31.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,188 |
| Average Volume | 54,951 |
| Open | 93.70 |
| Previous Close | 93.80 |
| Day's Range | 90.60 - 98.10 |
| 52-Week Range | 74.00 - 159.60 |
| Beta | 0.81 |
| RSI | 66.92 |
| Earnings Date | Apr 27, 2026 |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the inter... [Read more]
Financial Performance
In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.
Financial StatementsNews
Devyser Diagnostics AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% revenue growth in fixed currencies, positive EBIT for the fourth straight quarter, and strong gross margins. The Cybergene acquisition and new Illumina agreement are set to boost future growth, with continued focus on profitable expansion and cash flow.
Devyser Diagnostics AB Earnings Call Transcript: Q4 2025
Record Q4 sales and profitability were achieved, with EBIT margin over 20% and strong cash flow. Growth was driven by new product launches, strategic acquisitions, and major partnerships, while cost discipline and regulatory progress support a positive outlook.
Devyser Diagnostics AB Earnings Call Transcript: Q3 2025
Q3 saw record revenue and improved profitability, with positive EBIT and strong growth in the Americas and Italy. New product launches and efficiency measures support a positive outlook, while reimbursement delays and gradual tender ramp-ups remain key watchpoints.
Devyser Diagnostics AB Earnings Call Transcript: Q2 2025
Record Q2 revenue and EBIT were driven by strong U.S. and distributor sales, new product launches, and operational efficiencies. The company is on track to meet its 2026 financial targets, with a robust cash position and continued investment in innovation.
Devyser Diagnostics AB Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 8% year-over-year to SEK 54.8 million, with gross margin rebounding to 83.4%. Strategic focus on clinical genetics and transplantation, new product launches, and regulatory milestones support confidence in meeting 2025 growth and profitability targets.
Devyser Diagnostics AB Earnings Call Transcript: Q4 2024
Q4 2024 marked the first profitable quarter, with revenue up 41.5% year-over-year and strong growth in EMEA and the Americas. Strategic partnerships, regulatory milestones, and a robust cash position support continued expansion and profitability focus in 2025.
Devyser Diagnostics AB Transcript: CMD 2024
Strong growth continues across hereditary, oncology, and transplantation, with a strategic shift toward NGS and software. U.S. expansion is prioritized via a dual lab/kit model, aiming for rapid Medicare coverage and FDA approvals. Financial targets for growth, margin, and profitability remain on track.
Devyser Diagnostics AB Earnings Call Transcript: Q3 2024
Q3 saw modest revenue growth and a temporary drop in gross margin due to facility move costs, but strong performance in Europe and Asia and a major order from Thermo Fisher set up a robust Q4. Strategic FDA partnership and new product launches are expected to drive future growth.
Devyser Diagnostics AB Earnings Call Transcript: Q2 2024
Record Q2 sales and strong organic growth were driven by major tender wins, expanded global partnerships, and high-margin consumables. One-off costs from facility moves and U.S. expansion impacted EBIT, but guidance remains for continued high growth and margin improvement.